Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection.
Comp Immunol Microbiol Infect Dis
; 65: 137-143, 2019 Aug.
Article
em En
| MEDLINE
| ID: mdl-31300103
ABSTRACT
HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to ï¬ght ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leishmania infantum
/
Vacinas de DNA
/
Vacinas contra Leishmaniose
/
Leishmaniose Visceral
Limite:
Animals
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article